The purpose of this study is to learn more about amyotrophic lateral sclerosis (ALS) and other related neurodegenerative diseases, including frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progressive muscular atrophy (PMA) and multisystem proteinopathy (MSP). More precisely, the investigator wants to identify the links that exist between the disease phenotype (phenotype refers to observable signs and symptoms) and the disease genotype (genotype refers to your genetic information). The investigator also wants to identify biomarkers of ALS and related diseases.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Rates of change in revised ALS functional rating scale (ALSFRS-R)
Timeframe: 48 months
Rates of change in Slow vital capacity (SVC)
Timeframe: 48 months
Rates of change in Spastic paraplegia rating scale (SPRS)
Timeframe: 48 months
Rates of change in Edinburgh Cognitive and Behavioral ALS Screen (ECAS)
Timeframe: 48 months
ALS Health Index (ALS-HI)
Timeframe: 48 months
Serum
Timeframe: 48 months
Cerebrospinal Fluid (CSF)
Timeframe: 48 months